Now that clinical guidelines discourage using single-dose nevirapine, and as clinical practice shifts to initiating zidovudine earlier in the Indian HIV-positive pregnant population, there may be factors other than anemia or other clinical factors, including continuity of antenatal care utilization, that influence the use of zidovudine for PMTCT, and its associated clinical outcomes.